Cargando…

A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections

Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenge...

Descripción completa

Detalles Bibliográficos
Autores principales: Mideo, Nicole, Bailey, Jeffrey A., Hathaway, Nicholas J., Ngasala, Billy, Saunders, David L., Lon, Chanthap, Kharabora, Oksana, Jamnik, Andrew, Balasubramanian, Sujata, Björkman, Anders, Mårtensson, Andreas, Meshnick, Steven R., Read, Andrew F., Juliano, Jonathan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753362/
https://www.ncbi.nlm.nih.gov/pubmed/26817485
http://dx.doi.org/10.1093/emph/eov036
_version_ 1782415851064918016
author Mideo, Nicole
Bailey, Jeffrey A.
Hathaway, Nicholas J.
Ngasala, Billy
Saunders, David L.
Lon, Chanthap
Kharabora, Oksana
Jamnik, Andrew
Balasubramanian, Sujata
Björkman, Anders
Mårtensson, Andreas
Meshnick, Steven R.
Read, Andrew F.
Juliano, Jonathan J.
author_facet Mideo, Nicole
Bailey, Jeffrey A.
Hathaway, Nicholas J.
Ngasala, Billy
Saunders, David L.
Lon, Chanthap
Kharabora, Oksana
Jamnik, Andrew
Balasubramanian, Sujata
Björkman, Anders
Mårtensson, Andreas
Meshnick, Steven R.
Read, Andrew F.
Juliano, Jonathan J.
author_sort Mideo, Nicole
collection PubMed
description Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenges of polyclonal infections without requiring a genetic marker for resistance. Methodology: Clinical samples from patients treated with artemisinin combination therapy were collected from Tanzania and Cambodia. By deeply sequencing a hypervariable locus, we quantified the relative abundance of parasite subpopulations (defined by haplotypes of that locus) within infections and revealed evolutionary dynamics during treatment. Slow clearance is a phenotypic, clinical marker of artemisinin resistance; we analyzed variation in clearance rates within infections by fitting parasite clearance curves to subpopulation data. Results: In Tanzania, we found substantial variation in clearance rates within individual patients. Some parasite subpopulations cleared as slowly as resistant parasites observed in Cambodia. We evaluated possible explanations for these data, including resistance to drugs. Assuming slow clearance was a stable phenotype of subpopulations, simulations predicted that modest increases in their frequency could substantially increase time to cure. Conclusions and implications: By characterizing parasite subpopulations within patients, our method can detect rare, slow clearing parasites in vivo whose phenotypic effects would otherwise be masked. Since our approach can be applied to polyclonal infections even when the genetics underlying resistance are unknown, it could aid in monitoring the emergence of artemisinin resistance. Our application to Tanzanian samples uncovers rare subpopulations with worrying phenotypes for closer examination.
format Online
Article
Text
id pubmed-4753362
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47533622016-02-16 A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections Mideo, Nicole Bailey, Jeffrey A. Hathaway, Nicholas J. Ngasala, Billy Saunders, David L. Lon, Chanthap Kharabora, Oksana Jamnik, Andrew Balasubramanian, Sujata Björkman, Anders Mårtensson, Andreas Meshnick, Steven R. Read, Andrew F. Juliano, Jonathan J. Evol Med Public Health Original Research Article Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when infections contain multiple parasite clones, which is the norm in high transmission settings in Africa. Our aim was to develop and apply an approach for detecting resistance that overcomes the challenges of polyclonal infections without requiring a genetic marker for resistance. Methodology: Clinical samples from patients treated with artemisinin combination therapy were collected from Tanzania and Cambodia. By deeply sequencing a hypervariable locus, we quantified the relative abundance of parasite subpopulations (defined by haplotypes of that locus) within infections and revealed evolutionary dynamics during treatment. Slow clearance is a phenotypic, clinical marker of artemisinin resistance; we analyzed variation in clearance rates within infections by fitting parasite clearance curves to subpopulation data. Results: In Tanzania, we found substantial variation in clearance rates within individual patients. Some parasite subpopulations cleared as slowly as resistant parasites observed in Cambodia. We evaluated possible explanations for these data, including resistance to drugs. Assuming slow clearance was a stable phenotype of subpopulations, simulations predicted that modest increases in their frequency could substantially increase time to cure. Conclusions and implications: By characterizing parasite subpopulations within patients, our method can detect rare, slow clearing parasites in vivo whose phenotypic effects would otherwise be masked. Since our approach can be applied to polyclonal infections even when the genetics underlying resistance are unknown, it could aid in monitoring the emergence of artemisinin resistance. Our application to Tanzanian samples uncovers rare subpopulations with worrying phenotypes for closer examination. Oxford University Press 2016-01-27 /pmc/articles/PMC4753362/ /pubmed/26817485 http://dx.doi.org/10.1093/emph/eov036 Text en © The Author(s) 2016. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Mideo, Nicole
Bailey, Jeffrey A.
Hathaway, Nicholas J.
Ngasala, Billy
Saunders, David L.
Lon, Chanthap
Kharabora, Oksana
Jamnik, Andrew
Balasubramanian, Sujata
Björkman, Anders
Mårtensson, Andreas
Meshnick, Steven R.
Read, Andrew F.
Juliano, Jonathan J.
A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
title A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
title_full A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
title_fullStr A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
title_full_unstemmed A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
title_short A deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
title_sort deep sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753362/
https://www.ncbi.nlm.nih.gov/pubmed/26817485
http://dx.doi.org/10.1093/emph/eov036
work_keys_str_mv AT mideonicole adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT baileyjeffreya adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT hathawaynicholasj adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT ngasalabilly adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT saundersdavidl adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT lonchanthap adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT kharaboraoksana adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT jamnikandrew adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT balasubramaniansujata adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT bjorkmananders adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT martenssonandreas adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT meshnickstevenr adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT readandrewf adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT julianojonathanj adeepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT mideonicole deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT baileyjeffreya deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT hathawaynicholasj deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT ngasalabilly deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT saundersdavidl deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT lonchanthap deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT kharaboraoksana deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT jamnikandrew deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT balasubramaniansujata deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT bjorkmananders deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT martenssonandreas deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT meshnickstevenr deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT readandrewf deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections
AT julianojonathanj deepsequencingtoolforpartitioningclearanceratesfollowingantimalarialtreatmentinpolyclonalinfections